GIPR Function in the Central Nervous System: Implications and Novel Perspectives for GIP-Based Therapies in Treating Metabolic Disorders.


Journal

Diabetes
ISSN: 1939-327X
Titre abrégé: Diabetes
Pays: United States
ID NLM: 0372763

Informations de publication

Date de publication:
09 2021
Historique:
received: 07 04 2021
accepted: 21 05 2021
pubmed: 29 6 2021
medline: 9 11 2021
entrez: 28 6 2021
Statut: ppublish

Résumé

During the past decade, pharmaceutical engineering of unimolecular agents has revealed the therapeutic potential of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism. From this work, one of the most intriguing findings is that engagement of GIPR enhances the weight loss profile of glucagon-like peptide 1 (GLP-1)-based therapeutics. Consequently, this pharmacological approach, in combination with novel

Identifiants

pubmed: 34176786
pii: dbi21-0002
doi: 10.2337/dbi21-0002
pmc: PMC8576420
doi:

Substances chimiques

Glucagon-Like Peptide-1 Receptor 0
Receptors, Gastrointestinal Hormone 0
Gastric Inhibitory Polypeptide 59392-49-3
Glucagon-Like Peptide 1 89750-14-1
gastric inhibitory polypeptide receptor D6H00MV7K8

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1938-1944

Subventions

Organisme : Medical Research Council
ID : MC_UU_12012/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/3
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106263/Z/14/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106262/Z/14/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/5
Pays : United Kingdom

Informations de copyright

© 2021 by the American Diabetes Association.

Références

J Comp Neurol. 2010 Apr 1;518(7):943-62
pubmed: 20127760
Peptides. 2018 Feb;100:173-181
pubmed: 29412817
Behav Brain Res. 2010 May 1;209(1):1-12
pubmed: 20035790
Biochem Biophys Res Commun. 2017 Aug 19;490(2):247-252
pubmed: 28610922
Nat Metab. 2021 Apr;3(4):530-545
pubmed: 33767443
Endocrinology. 1993 Dec;133(6):2861-70
pubmed: 8243312
Nutr Diabetes. 2016 May 02;6:e208
pubmed: 27136446
Nat Med. 2002 Jul;8(7):738-42
pubmed: 12068290
Mol Metab. 2019 Oct;28:14-25
pubmed: 31451430
Neuron. 2021 Feb 3;109(3):461-472.e5
pubmed: 33278342
Horm Metab Res. 1991 Nov;23(11):517-21
pubmed: 1816061
Mol Metab. 2018 Dec;18:3-14
pubmed: 30473097
Cell Metab. 2019 Nov 5;30(5):987-996.e6
pubmed: 31447324
J Clin Invest. 1981 Oct;68(4):1106-7
pubmed: 7287903
Neuropharmacology. 2012 Apr;62(5-6):1916-27
pubmed: 22227019
PLoS One. 2012;7(7):e40156
pubmed: 22802954
J Clin Invest. 2007 Jan;117(1):143-52
pubmed: 17187081
Nat Commun. 2020 Oct 5;11(1):4981
pubmed: 33020469
Sci Transl Med. 2018 Dec 19;10(472):
pubmed: 30567927
Cent Nerv Syst Agents Med Chem. 2011 Sep 1;11(3):210-22
pubmed: 21919873
Mol Metab. 2019 Feb;20:51-62
pubmed: 30578168
Cell Metab. 2021 Apr 6;33(4):833-844.e5
pubmed: 33571454
Int J Clin Pract. 2014 Jun;68(6):682-91
pubmed: 24548654
Diabetes Metab Syndr Obes. 2017 Sep 29;10:403-412
pubmed: 29033597
Sci Transl Med. 2013 Oct 30;5(209):209ra151
pubmed: 24174327
Diabetes. 2019 May;68(5):906-917
pubmed: 30626611
J Endocrinol. 2020 Apr;245(1):13-20
pubmed: 31977316
Cell Metab. 2018 Apr 3;27(4):740-756
pubmed: 29617641
Int J Obes (Lond). 2014 Aug;38(8):1019-26
pubmed: 24166067
Lancet. 2018 Nov 17;392(10160):2180-2193
pubmed: 30293770
Nat Rev Neurosci. 2011 Mar;12(3):169-82
pubmed: 21331083
J Am Coll Nutr. 1988 Jun;7(3):241-7
pubmed: 3392357
Diabetes Obes Metab. 2018 Jan;20(1):60-68
pubmed: 28598027
Life Sci. 2000;66(2):91-103
pubmed: 10666005
J Endocrinol. 2011 Mar;208(3):265-71
pubmed: 21212092
Cell Metab. 2020 Apr 7;31(4):679-698
pubmed: 32187525
Cell Metab. 2012 Sep 5;16(3):296-309
pubmed: 22902836
J Neurosci. 2015 Mar 18;35(11):4582-6
pubmed: 25788675
J Clin Invest. 2014 Oct;124(10):4473-88
pubmed: 25202980
Elife. 2018 Aug 21;7:
pubmed: 30129922
JCI Insight. 2020 Mar 26;5(6):
pubmed: 32213703
Mol Metab. 2019 Dec;30:72-130
pubmed: 31767182
Diabetes. 2008 Jan;57(1):190-8
pubmed: 17928394
Am J Clin Nutr. 2012 Apr;95(4):989-94
pubmed: 22434603
Diabetes. 2017 Sep;66(9):2363-2371
pubmed: 28667118
N Engl J Med. 2021 Mar 18;384(11):989-1002
pubmed: 33567185
Trends Endocrinol Metab. 2020 Jun;31(6):410-421
pubmed: 32396843
ACS Pharmacol Transl Sci. 2018 Jun 28;1(1):3-11
pubmed: 32219200
Diabetes Obes Metab. 2017 Mar;19(3):336-347
pubmed: 27860132
J Clin Invest. 2019 Aug 12;129(9):3786-3791
pubmed: 31403469
Diabetologia. 2009 Feb;52(2):289-298
pubmed: 19082577
J Immunol. 2014 Oct 15;193(8):4002-9
pubmed: 25217161
Mol Metab. 2014 Jan 08;3(2):209-15
pubmed: 24634830
Mol Metab. 2020 Feb;32:44-55
pubmed: 32029229
Regul Pept. 1983 Sep;7(1):3-8
pubmed: 6359287
Peptides. 1994;15(2):297-302
pubmed: 8008635
Regul Pept. 2007 Aug 16;142(3):138-45
pubmed: 17395281
Nature. 2015 Feb 12;518(7538):197-206
pubmed: 25673413
Mol Metab. 2021 Nov;53:101240
pubmed: 33962048

Auteurs

Ricardo J Samms (RJ)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN samms_ricardo_j@lilly.com aea35@medschl.cam.ac.uk.

Kyle W Sloop (KW)

Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN.

Fiona M Gribble (FM)

Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.

Frank Reimann (F)

Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.

Alice E Adriaenssens (AE)

Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K. samms_ricardo_j@lilly.com aea35@medschl.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH